# HLA Class I Engageability — Hackathon Submission Package
**Research track · "Built with Claude: Life Sciences" · goal: a reproducible finding**
*Framing + figure list. Companion file: `VIDEO_script_3min.md`.*

---

## Part 1 — The solidified framing

### The one-sentence pitch
> We set out to test whether a single HLA class I "immunogenic potency" trades cancer protection against autoimmune risk; we built a new, validated, sequence-derived axis of that potency (**engageability**), proved that potency is **not one number but several independent axes**, showed with math and power analysis **why public data cannot answer the germline trade-off** — and then followed the statistical power to where the data *can* speak, recovering a clean positive control (**B2M loss-of-function selection**) and a **novel, reproducible finding: a locus-wide HLA-B loss/retention hierarchy under somatic HLA-LOH, with B\*58:01 the one allele individually singled out as preferentially lost.**

### Why this framing wins the research track
The research track rewards a *reproducible finding produced with disciplined method*. This project's honest situation is: the headline hypothesis returned a **bounded null**, but the pipeline generated (a) a genuinely new measurement, (b) a hard conceptual result about identifiability, and (c) at least one clean, novel, statistically-significant somatic finding. The strongest submission does not hide the null — it makes the **discipline** the story and lets the discipline *deliver a real finding at the end*. Judges reward "we knew when to stop believing our own result, and we found the place the data was actually powered."

So the arc is **Question → New tool → Honest turn (multi-axis + non-identifiability) → Follow the power → Reproducible finding → Method**. Five layers, each true, each defensible.

### The four things we can actually stand behind

**1. A new, validated axis: engageability.**
A per-allele score of how permissively an allele's α1/α2 **TCR-facing crest** admits *diverse* TCR docking (not clone-specific contacts). Built for all **676** class I alleles from 243 crystal complexes. It passes every construction gate:
- Landmark reconciliation vs the 1AO7 crystal: **0 mismatches / 182 positions**.
- Recovers canonical restriction determinants: **R65 94%, A69 95%, Q155 97%**.
- Blend-robust to metric definition: Spearman **0.925** (pre-registered bar 0.8).
- **Orthogonal to HED** (the established peptide-breadth axis): Pearson **r = −0.02** (Spearman −0.04) across 676 alleles — a genuinely non-redundant dimension.

**2. The conceptual headline: potency is a multi-axis decomposition, not a scalar.**
Run through the *identical* cancer specification, the axes separate:
- **HED (breadth)** gives a negative, CI-excludes-zero coefficient (clustered β ≈ −0.14 to −0.16, p_t 0.028–0.042).
- **Engageability** gives a positive, non-significant coefficient (β ≈ +0.06 to +0.08, p_t 0.13–0.26) — *opposite sign*.
- Against one common permutation null they split (HED p = 0.088 vs engageability p = 0.286).
- **Presentation capacity** (a per-allele PHBR analog) is a real, well-resolved axis (SD 10–14× the measurement SE) whose allele-level correlation with HED (A ρ = −0.45) **vanishes at the ~6 independent supertype contrasts per locus** — "that ceiling is the finding."
- **CD8 / α3 engagement** is the conserved axis: **5 footprints over 674 alleles (93.2% modal), HLA-B entirely invariant** — near-constant, carried separately.
→ "Immunogenic potency" factors into breadth × engagement × presentation × (conserved) CD8 — three that vary, one that doesn't, all mutually non-redundant.

**3. Why the germline trade-off is unanswerable on public data — proven, not asserted.**
This is the intellectual high point and it converts a null into a *result*.
- **Effective N ≈ 8 supertype meeting-points**, not 400 allele rows: cancer favorability is constant within supertype, and the independent two-arm overlap (an allele carrying *both* its own ICB hazard ratio *and* an autoimmune odds ratio) is structurally **N = 0**. The direct antagonistic-pleiotropy test is ρ = +0.037, **p = 0.90** — and its sign runs *against* the hypothesis.
- **Identifiability theorem:** an analysis that regresses outcome on allele potency is *structurally incapable* of separating the two arms of the trade-off (escape vs elimination) — it is the joint flexibility of the escape and elimination functions that destroys identification, **not the cohort size**. Escape must be *measured*, never inferred from a marginal outcome association.
- **Power analysis, pre-registered blind:** in the TCR-diversity arm, the design's power **never reaches 80% at any ρ ≤ 0.95** given the empirical noise; resolving ρ = 0.4 would need ~500 distinct crest profiles, but the entire catalog holds only ~150 and VDJdb covers 11. The observed ρ = +0.08 (permutation p = 0.82) is *uninformative by construction* — and that was stated before the number was seen.

**4. The reproducible finding: follow the power to somatic escape (MSK-IMPACT, ~50k tumors).**
Where germline outcome data is too thin, the somatic escape data is deep — and the pipeline delivers:
- **Positive control — B2M loss-of-function selection.** After removing target-size, reference-mismapping, and hypermutator confounds, the sole non-confoundable somatic selection signal in the antigen-presentation machinery is loss-of-function of **B2M** (truncating dN/dS ≈ 9.7, q = 3×10⁻⁴; frameshift ≈ 30.7, q = 1.3×10⁻¹⁰). **HLA-C is a built-in negative control and passes** (collapses to a neutral 1.87, CI includes 1). B2M is the known escape gene (Zaretsky 2016) — this *validates the pipeline*.
- **Novel finding — a locus-wide HLA-B loss/retention hierarchy, with B\*58:01 the one allele individually singled out as preferentially lost.** The primary result is at the *locus* level: HLA-B carries robust allele-intrinsic loss-preference structure across 15,704 within-patient LOH events (Bradley–Terry LRT **p = 0.0002**), and it **survives dropping its most influential alleles** — so the pattern is locus-wide, not one outlier. Resolved to individual alleles, four separate from the HLA-B (and HLA-A) locus mean at FDR < 0.05, and they split by direction: **B\*58:01 is preferentially *lost* (fraction-lost 0.665, FDR 0.003, n = 164) — the only individually significant loss-biased allele — while B\*07:02 (0.439), B\*08:01 (0.430) and A\*01:01 (−0.203) are significantly *retained*.** (At uncorrected thresholds several more HLA-B alleles separate from the mean, and a few small-n alleles show higher raw loss fractions, but they shrink toward 0.5 and do not survive correction — so they are not claimable.) The B\*58:01 loss signal survives a four-check adversarial review; it is **not a read-mapping artifact** (the divergence-from-reference negative control runs *opposite* to the artifact prediction, HLA-A ρ = −0.51, p = 0.005); it is **not haplotype-driven** (concordance p = 0.056, n.s.); and it is **not pre-empted by the cohort's own paper** (Bandlamudi 2026 reports allele-preferential loss only *conditioned* on driver/neoantigen context — this unconditional, allele-intrinsic ranking is new). The honest headline is therefore *"HLA-B has an intrinsic loss/retention hierarchy under immune escape, and B\*58:01 sits at its loss-prone extreme"* — a stronger, more general statement than a single-allele outlier.

### The honesty layer (state it — it's a selling point, not a liability)
The pipeline **caught its own false positives** three times, each pre-registered and each reversed on an honest control:
- Drug-HSR "signal" was a B58-supertype degeneracy — collapsed to null when independent contrasts were added (anchor percentile 75.6 → 60.9; MWU p 0.124 → 0.398).
- An infection-control sub-signal (z_het, ρ = +0.63 in HLA-B) collapsed to ρ = −0.03 when non-HIV viruses were added — a collinear-cluster artifact.
- The engageability→LOH-loss signal at HLA-B (β ≈ 0.60) was **absorbed by the Bw4/Bw6 KIR-ligand epitope** (β → 0.325, p = 0.067) — a KIR confound outside the crest, not engageability. We report it as disqualified.

And it reproduced a published positive control cleanly (KRAS G12V restricting-allele preferential loss OR = 5.06, p = 3×10⁻⁴; TP53 R175H/A\*02:01 loss in colorectal OR = 3.64).

### Clinical significance — why the loss/retention hierarchy matters

**HLA-LOH is one of the most common immune-escape events in solid tumors, and *which* allele a tumor chooses to delete is not random — it is an in-human genetic readout of immune pressure.** A tumor that loses one HLA allele but keeps the other is telling you which of its own antigen-presenting molecules was hurting it most. So an allele-intrinsic loss/retention hierarchy is, in effect, a natural pooled screen — run across ~50,000 patients — for *which restriction elements matter to anti-tumor immunity and which the tumor can afford to keep*. That is directly actionable for target selection in TCR-based therapy, in two complementary ways:

- **Preferentially *lost* alleles (B\*58:01) flag high-immune-pressure — but also escape liability.** If tumors repeatedly delete B\*58:01, the peptides it presents are plausibly among the ones driving recognition (why else escape them?). That makes B\*58:01-restricted neoantigens attractive to *identify and characterize* — but it also warns that a therapy built on a B\*58:01-restricted target carries built-in escape risk, because the tumor already has a demonstrated route to shed exactly that allele. Loss-proneness is thus both a discovery signal and a resistance forecast.
- **Preferentially *retained* alleles (B\*07:02, B\*08:01, A\*01:01) are candidate escape-*durable* restriction elements.** A TCR-T or TCR-mimic therapy whose target is presented on an allele the tumor is statistically *reluctant to lose* is less likely to be defeated by HLA-LOH — arguably the single most important durability property for an HLA-restricted therapeutic. The retained end of the hierarchy is therefore a data-driven shortlist of "safe harbor" restriction elements for durable TCR-based design.

**One honest mechanistic fork to carry with the clinical read:** B\*58:01 is a Bw4 allele, and at HLA-B the lost homolog is Bw4 in ~73% of discordant events. So the loss pressure on B\*58:01 may reflect **CD8 T-cell escape, NK/KIR (KIR3DL1-ligand) evasion, or both** — the project does not yet separate them. This is not a caveat that weakens the finding so much as it *defines the first experiment*: the therapeutic interpretation (target its peptides / avoid it as a restriction element) depends on which arm of immunity is driving the loss.

### Future work this drives (the translational program)

1. **Immunopeptidomics + prediction on the hierarchy.** Enumerate and compare the presented peptide repertoires — tumor neoantigens and shared self/tumor-associated antigens — of the loss-prone allele (B\*58:01) vs the retained alleles (B\*07:02, B\*08:01, A\*01:01), by mass-spec immunopeptidomics and NetMHCpan/capacity prediction. Hypothesis: B\*58:01 presents a richer or more immunogenic escape-relevant set.
2. **Does loss-proneness track immunogenicity?** Test whether B\*58:01-restricted peptides drive stronger, more frequent T-cell responses (functional T-cell assays, public TCR databases) than retained-allele-restricted peptides — the direct test of "tumors delete what hurts them."
3. **Prioritize escape-durable targets.** Build a candidate list of tumor-shared antigens presented on *retained* alleles as escape-resistant restriction elements for TCR-T / TCR-mimic development, and model expected durability against HLA-LOH.
4. **Dissect the CD8-vs-NK mechanism.** Separate T-cell pressure from KIR/Bw4-driven NK evasion for the B-locus loss signal (KIR-genotype stratification; NK vs CD8 functional readouts) — decides whether the therapeutic move is "target B\*58:01 peptides" or "beware B\*58:01 as an NK-linked escape route."
5. **Validate with paired data and connect to engageability.** Confirm the hierarchy in an independent cohort carrying HLA typing + LOH calls + outcomes, and re-ask whether the loss/retention ranking aligns with any sequence-derived axis (engageability, HED, capacity) once the Bw4/Bw6 KIR confound is properly adjusted — the honest next step after that link dissolved at HLA-B in this project.
6. **Power the study on institutional data — a >100,000-patient controlled-access cohort.** The public/summary-statistic ceiling is the binding constraint throughout this project (effective N ≈ 8 on the germline arm; n = 164 events on the B\*58:01 finding, too few to stratify). A large institutional sequencing cohort (e.g. a tumor-genomics registry of >100k patients with paired germline HLA typing, HLA-LOH calls, and clinical outcomes — the kind held privately, not in public releases) is what powers the questions this project could only frame: **per-cancer-type stratification of the loss/retention hierarchy** (which indications drive B\*58:01 loss), the joint benefit/toxicity engageability biomarker test in a single ICB-treated cohort, and read-level re-calling that would finally separate real loss from residual mapping artifact. This is the concrete path from "reproducible pan-cancer signal" to "indication-specific, clinically actionable target list."

### Honest limitations to keep on the record
Association- and sequence-level, not causal or clinical. HED and the antagonistic-pleiotropy *concept* are prior work (our contributions are the engageability metric, the orthogonality decomposition, the identifiability analysis, and the somatic findings). Presentation capacity is a PHBR analog, not novel. The somatic escape arms do **not** converge with the germline engageability arm — they measure different estimands on different substrates, and we fence that explicitly. B\*58:01's loss *mechanism* (immune pressure vs structural) is left open. **The B\*58:01 loss and B\*07:02 / B\*08:01 / A\*01:01 retention finding is pan-cancer and tumor-type-agnostic** — the within-patient paired design *controls for* cancer type (it cancels as a within-patient confound) but does not *resolve* the signal per cancer type, and at n = 164 events a per-type breakdown is underpowered (the analysis already imposes a ≥20-event floor). Whether B\*58:01 loss concentrates in specific indications is left to the powered institutional cohort above.

### One framing decision for you to confirm
I recommend leading the video with **the metric + the multi-axis decomposition** as the *contribution*, and landing on **B\*58:01 + B2M** as the *concrete reproducible finding*, with the identifiability/power story as the bridge that justifies the pivot. The alternative is to lead with B\*58:01 as the headline finding and treat engageability as the framework that motivated the search. I think the first is the stronger hackathon story (novelty + a clean finding + rigor), but the second is more "single-finding-forward" if that's what the judges weight. Flagging so you can steer.

---

## Part 2 — Figure list for the final presentation

Ordered to match the video. "Grade" = A (hero / on-screen anchor), B (strong support), C (backup / appendix). Paths are relative to the `Claude Science Hackathon` folder. Where a document embedded the figure as an artifact rather than a saved PNG, I mapped it to the closest saved file — **confirm the exact panel** on the ones marked ⚠.

| # | Figure (file) | Grade | What it shows / why it's in the video |
|---|---|---|---|
| 1 | Project file `fig_F1_hypothesis_schematic.png` *(in the Hackathon project, not the device folder)* | A | The antagonistic-pleiotropy question in one schematic — opens the story. |
| 2 | `cancer arm/F2_tcr_footprint.png` | A | The TCR-facing crest on the class I fold (VARIABLE n=14 / CONSERVED n=12; R65/A69/Q155) — shows *what engageability measures*. |
| 3 | `cancer arm/F1_engageability_vs_HED.png` | A | Engageability vs HED, 676 alleles, r = −0.02 — the "new, non-redundant axis" money shot. |
| 4 | `HED pos control arm/fig_hed_vs_engageability_sidebyside.png` | A | **Decomposition hero:** HED (negative, significant) vs engageability (positive, n.s.) on the *same* cancer spec — potency is not one number. |
| 5 | `capacity arm/fig_capacity_vs_hed.png` | B | Capacity vs HED with supertype points — the third axis, and the "signal vanishes at the honest grain" ceiling. |
| 6 | `engageability master/identifiability_theory.png` | A | Non-identifiability: one outcome curve, three different escape/elimination factorizations — *why* outcome-on-potency can't separate the arms. |
| 7 | `engageability-tcr diversity arm/fig_mde_power_curve.png` | A | Blind power curve never reaching 80% — the honest-null / "underpowered by construction" beat. |
| 8 | `tradeoff arm/fig_tradeoff_engageability_two_arm.png` | B | The two-arm trade-off result itself (ρ = +0.037, p = 0.90) — the bounded null, shown plainly. |
| 9 | `somatic selection of apm arm/fig_dnds_stratified.png` ⚠ | A | Mismapping diagnostic: HLA-A inflates, **HLA-C collapses to neutral, B2M holds** — the pivot's positive control + negative control in one panel. |
| 10 | `somatic selection of apm arm/fig_dnds_apm.png` ⚠ | B | Per-gene dN/dS landscape — B2M loss-of-function towering over the APM (q ≈ 10⁻¹⁰). |
| 11 | `LOH arm/fig_loh_BT_strengths.png` | A | **The finding:** Bradley–Terry per-locus loss-preference caterpillar, B\*58:01 loss-biased among the significant HLA-B alleles. |
| 12 | `LOH arm/fig_s11_negcontrol.png` | A | Divergence-vs-loss negative control running *opposite* to the read-mapping artifact — proves B\*58:01 is real. |
| 13 | `LOH arm/fig_g1_positive_control.png` | B | Reproduced published positive control (KRAS G12V OR = 5.06) — pipeline validation. |

*(The cancer-mimic / viral-mimicry structural demo is excluded from the submission and is not a figure here.)*

**Backup / appendix (grade C):** `HED arm/fig_hed_by_locus.png` (B>A>C breadth), `autoimmune risk arm/fig_autoimmune_risk_axis.png` (protective→risk gradient, B\*57:01 multi-anchoring), `engageability master/fig_axis_orthogonality.png` (per-locus orthogonality), `peptide selection/fig1_iedb_ascertainment_bias.png` (A\*02:01 = 36.8% — circularity firewall), `capacity arm/fig_E1_capacity_two_arm.png` (capacity outcome null), `HLA allele freq/fig_distinct_profiles_vs_floor.png` (effective-df robustness), `LOH arm/RESULTS`/`fig_s10_locusB_battery.png` (the Bw4/Bw6 KIR self-refutation).

**Tight 6-figure cut (if 3 minutes is punishing):** 2 (crest) → 3 (orthogonality) → 4 (decomposition) → 7 (power/why-null) → 9 (B2M/HLA-C control) → 11 (B\*58:01 finding).

---

## Part 3 — Reviewer Q&A / technical appendix

*Answers to the five questions a judge is most likely to press on. Written to be read aloud or dropped into deck speaker notes. Every number traces to the session results docs (`identifiability_note.md`, `RESULTS_selection_arm.md`, `RESULTS_LOH_arm_comprehensive.md`).*

### Q1. What exactly is the identifiability theorem, and why does it matter?

Model each allele's expected contribution to ICB benefit as a **product** of two processes that both increase with the allele's potency `e`: elimination pressure `s(e)` (how hard its presentation drives T-cell killing) and escape probability `h(e)` (the chance the tumor has already disabled that allele's presentation via HLA-LOH, B2M loss, or APM silencing):

> **Δ(e) = (1 − h(e)) · s(e)**

The allele-level observable is only a monotone readout of Δ — you never see `s` and `h` separately. The theorem: **the escape term cannot be recovered from a regression of outcome on potency without an untestable parametric assumption about the shape of elimination.** A product does not determine its factors — for any escape curve `h`, one can back out an `s` that reproduces the identical Δ. Formally, identification depends on which function you constrain: fix `h`, leave `s` free → escape sensitivity only *partially* identified (unbounded set); fix *both* → point-identified. **The obstacle is the assumption, not the sample size** — a larger cohort only sharpens the single observable curve; it never separates the two factors.

Three consequences, all load-bearing:
- An **against-prior sign** (higher potency → *worse* ICB benefit) is a structural prediction, not an anomaly: past the peak at `e* = 1/b`, alleles sit on the descending limb where escape dominates. The cancer arm's "wrong-direction" sign is expected.
- A **null trade-off test is consistent with a strong underlying trade-off**: averaging ascending-limb (+) and descending-limb (−) alleles pulls the marginal slope toward zero. The null is *uninformative*, not negative.
- The only assumption-free fix is to **measure escape directly** — e.g. a within-patient homolog LOH contrast, observing `h` while holding patient, tumor, and treatment fixed. **This theorem is what justifies the pivot to the LOH data.**

*(Credibility note: the source doc visibly corrected its own earlier overclaims — it does not assert "always non-monotone" or "unrecoverable regardless of cohort count," both false as written. Point at that self-correction.)*

### Q2. Why is B2M loss-of-function the positive control, and how does dN/dS validate it?

**dN/dS** is the ratio of protein-changing (nonsynonymous) to silent (synonymous) mutation rate, normalized to neutral expectation: ≈1 = neutral, **>1 = positive selection** (tumor is favored for breaking the gene), <1 = purifying. The arm uses dNdScv (trinucleotide-aware, background fit genome-wide over 3.6M substitutions) and splits by consequence class, so *truncating* dN/dS isolates loss-of-function.

For B2M the loss-of-function signal is huge: **truncating SNVs dN/dS ≈ 9.7 (q = 3×10⁻⁴); frameshift indels dN/dS ≈ 30.7 (q = 1.3×10⁻¹⁰)** — knockouts occurring ~10–30× above neutral. That is a clean statistical statement that tumors are *selected* to destroy B2M.

Why a positive *control* rather than a discovery: B2M (β2-microglobulin) is the invariant light chain every class-I HLA needs to reach the cell surface — knock it out and the tumor loses *all* class-I presentation and goes dark to CD8 T-cells. It is the textbook, experimentally proven escape gene (Zaretsky et al. 2016, acquired anti-PD-1 resistance). A working escape-detection pipeline *must* recover it; recovering it cleanly proves the method. It is also the ideal validator because it is monomorphic, on-panel, and mapping-clean — free of the artifacts that hit the HLA loci.

### Q3. How is HLA-C a built-in negative control?

The classical HLA loci are the most polymorphic genes in the genome; short-read sequencing aligns to one reference haplotype, so a patient's *germline* HLA differences get miscalled as *somatic* mutations — a reference-mismapping artifact that inflates apparent truncating dN/dS at HLA-A and HLA-B. The diagnostic: mismapped calls are germline and therefore **TMB-independent**, whereas real somatic selection scales with tumor mutation burden — so excluding hypermutators (MSI-H/POLE) *inflates* an artifact but *holds or deflates* a real signal. Under that exclusion:

| Locus/gene | Full cohort | MSI/POLE-excluded | Reading |
|---|---|---|---|
| HLA-A | 11.1 | **18.1** | rises → artifact |
| **HLA-C** | 4.1 | **1.87 (CI [0.61, 4.78] includes 1)** | collapses → neutral |
| B2M | 14.5 | **9.7 (CI excludes 1)** | holds → real |

HLA-C is the *least* polymorphic classical locus, so it should show the least mismapping — and it duly collapses to neutral. That is why it is a "built-in" negative control: a same-family locus expected to carry no real signal, already in the data, whose collapse confirms the HLA-A/B "signals" are artifacts (correctly quarantined). **HLA-A rises / HLA-C collapses / B2M holds** is the whole confound argument in one panel (Figure 3).

### Q4. Are there p-values for the preferentially *retained* alleles?

Yes — and they are as solid as the loss finding. Marginal exact binomial test (observed lost vs total, H₀: p = 0.5):

- **B\*08:01** — retained, frac_lost 0.430, **p = 1.56×10⁻⁴**
- **B\*07:02** — retained, frac_lost 0.439, **p = 4.43×10⁻⁴**
- *(B\*58:01 — lost, 0.665, p = 2.99×10⁻⁵, for comparison)*

All three clear global BH-FDR < 0.05 and within-locus Bonferroni < 0.05, all at HLA-B. On the primary Bradley–Terry estimand a fourth allele joins — **A\*01:01**, retained, centered log-strength −0.203, **FDR = 0.043**. So B\*07:02, B\*08:01, and A\*01:01 are individually significant *retention* signals in their own right — which is what makes them credible as candidate escape-durable restriction elements, not a soft counterpart to the loss result.

### Q5. What does it mean that B\*58:01 is Bw4?

Bw4 and Bw6 are two mutually exclusive public epitopes defined by the amino acids at residues ~77–83 of the HLA-B α1 helix; every HLA-B allele is one or the other, and **B\*58:01 is a Bw4 allele** (Bw4-80I, isoleucine at position 80). The functional point: **Bw4 is the ligand for KIR3DL1, an inhibitory NK-cell receptor** (and the activating KIR3DS1); Bw6 is not a KIR ligand. So Bw4 status governs *NK-cell* recognition — a different arm of immunity from CD8 T-cell recognition.

Why it matters here: among patients heterozygous for a Bw4 and a Bw6 allele, the **lost** homolog is Bw4 ~73% of the time, and the Bw4/Bw6 dimorphism **absorbed** the HLA-B engageability→loss signal (β 0.60 → 0.325, p = 0.067). Bw4's residues 77–83 lie **outside** the engageability crest footprint. So B\*58:01 being Bw4 creates a genuine mechanistic fork for its preferential loss: it could be lost because its presented peptides drive strong CD8 T-cell responses (classic escape), because it is a KIR3DL1 ligand and losing it re-tunes NK inhibition, or both. The project cannot separate these — which is exactly why the framing keeps B\*58:01's loss mechanism **open**, and why "dissect CD8 vs NK/KIR" is item 4 of the future-work program. For a judge, this is the sophisticated version of the finding: a real, correction-surviving loss signal whose *mechanism* is a well-posed next experiment, not a settled claim.
